Dupilumab Improves Health-Related Quality Of Life And Asthma Control In Patients With And Without Coexisting Type 2 Conditions: Results From The RAPID Study
Author(s)
Giselle S. Mosnaim, MD1, David Price, PhD2, Andréanne Côté, MD3, Vicente Plaza, MD4, Changming Xia, PhD5, Hashem Awad, MD6, Jason Kwah, PhD5.
1Endeavor Health, Evanston, IL, USA, 2Observational and Pragmatic Research Institute, Midview City, Singapore, 3Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, 6Sanofi, Cambridge, MA, USA.
1Endeavor Health, Evanston, IL, USA, 2Observational and Pragmatic Research Institute, Midview City, Singapore, 3Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, 6Sanofi, Cambridge, MA, USA.
Presentation Documents
OBJECTIVES: The coexistence of chronic rhinosinusitis (CRS) and nasal polyposis (NP) with asthma is common and impairs asthma control and quality of life. Multiple clinical trials have demonstrated dupilumab’s efficacy in patients with asthma, but real-world evidence is scarce. This analysis aimed to characterize patient-reported outcomes from a global, prospective, observational registry (RAPID; NCT04287621) of patients initiating dupilumab for asthma with and without coexisting CRS and/or NP (CRS-NP).
METHODS: Patients aged ≥12 years receiving dupilumab for moderate-to-severe, uncontrolled asthma in real-world practice were enrolled. We assessed unadjusted annualized rates of severe exacerbation and changes from baseline in scores on the 22-item Sino-Nasal Outcome Test (SNOT-22; score reduction indicates improvement in symptoms and reduced CRS impact), the 6-item Asthma Control Questionnaire (ACQ-6; score reduction indicates symptom improvement), and Mini Asthma Quality of Life Questionnaire (MiniAQLQ; increased scores indicate improvement in QoL). Outcomes were stratified by the presence and absence of CRS-NP.
RESULTS: Of 205 patients analyzed at 12 months, 94 had ongoing CRS-NP; 111 did not. Unadjusted annualized rates of severe exacerbation were similar in patients with (0.146) and without CRS-NP (0.129). In patients with CRS-NP, mean (standard deviation [SD]) 6- and 12-month scores had decreased on the SNOT-22 by 19.8 (20.7) and 17.0 (26.2), respectively, and on the ACQ-6 by 1.2 (1.2) and 1.3 (1.1); MiniAQLQ scores had increased by 1.5 (1.3) and 1.3 (1.4). In patients without CRS-NP, mean (SD) 6- and 12-month scores on the ACQ-6 had decreased by 1.3 (1.3) and 1.4 (1.1), and MiniAQLQ scores had increased by 1.4 (1.4) and 1.5 (1.3).
CONCLUSIONS: In this real-world analysis, dupilumab improved symptomatic asthma control and quality of life in patients with moderate-to-severe, uncontrolled asthma, irrespective of coexisting CRS-NP, and improved CRS symptoms in patients with CRS-NP.
METHODS: Patients aged ≥12 years receiving dupilumab for moderate-to-severe, uncontrolled asthma in real-world practice were enrolled. We assessed unadjusted annualized rates of severe exacerbation and changes from baseline in scores on the 22-item Sino-Nasal Outcome Test (SNOT-22; score reduction indicates improvement in symptoms and reduced CRS impact), the 6-item Asthma Control Questionnaire (ACQ-6; score reduction indicates symptom improvement), and Mini Asthma Quality of Life Questionnaire (MiniAQLQ; increased scores indicate improvement in QoL). Outcomes were stratified by the presence and absence of CRS-NP.
RESULTS: Of 205 patients analyzed at 12 months, 94 had ongoing CRS-NP; 111 did not. Unadjusted annualized rates of severe exacerbation were similar in patients with (0.146) and without CRS-NP (0.129). In patients with CRS-NP, mean (standard deviation [SD]) 6- and 12-month scores had decreased on the SNOT-22 by 19.8 (20.7) and 17.0 (26.2), respectively, and on the ACQ-6 by 1.2 (1.2) and 1.3 (1.1); MiniAQLQ scores had increased by 1.5 (1.3) and 1.3 (1.4). In patients without CRS-NP, mean (SD) 6- and 12-month scores on the ACQ-6 had decreased by 1.3 (1.3) and 1.4 (1.1), and MiniAQLQ scores had increased by 1.4 (1.4) and 1.5 (1.3).
CONCLUSIONS: In this real-world analysis, dupilumab improved symptomatic asthma control and quality of life in patients with moderate-to-severe, uncontrolled asthma, irrespective of coexisting CRS-NP, and improved CRS symptoms in patients with CRS-NP.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO178
Topic
Clinical Outcomes
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Biologics & Biosimilars